

Remarks

Claims 1-34 and 37 as amended and new claims 38-74 are pending in the application. Claims 35 and 36 are canceled without prejudice. Support for the amendments and new claims are found in the specification and present no new matter. For example, basis for specifying the newly claimed compounds can be found in particular in Examples 11, 12, 13, 14, 15, and 16 and in Table 20. Therapeutic end uses as defined in new claims 38, 42, and 44 are disclosed in the specification on page 84, line 30 to page 85, line 28.

Applicants respectfully submit that the claimed compounds are ready for examination and are in condition for allowance. A prompt and favorable notice to that effect is earnestly solicited.

Respectfully submitted,



William R. Boudreaux
Attorney for Applicants
Registration No. 35,796
Phone: 317-276-0755

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

October 4, 2004